{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:56:52Z","timestamp":1781672212390,"version":"3.54.5"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Analyzing the clinical characteristics, potential mechanisms, and treatment strategies of pembrolizumab-induced immune-related hepatitis to improve clinical management and treatment safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Case reports on pembrolizumab-induced immune-related hepatitis were retrieved from databases including PubMed, Science Direct, and Web of Science. Forty-two case reports were carefully reviewed and data on patient age, gender, primary disease, time to hepatitis onset, clinical manifestations, liver injury indicators, adverse reaction grading, treatment strategies, and prognosis were collected and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among these patients, 27 were male and 14 were female, and the average age was 64.2 years. The clinical manifestations included liver toxicity, neurological symptoms, skin reactions, systemic symptoms, and digestive symptoms. The time from initiation of pembrolizumab to the onset of immune-related hepatitis varied significantly. The shortest duration is 2 days, while the longest is 630 days. Corticosteroids were the primary treatment. The pathogenesis may be related to the dysregulation of liver immune tolerance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Before initiating pembrolizumab, clinicians should thoroughly evaluate patients' liver function and history of liver disease, and consider the hepatotoxicity of concurrent medications. During the use of pembrolizumab, regular monitoring of liver function should be conducted. If any abnormalities are found, appropriate treatment should be given promptly. Meanwhile, further research is needed to better understand pembrolizumab-induced immune-related hepatitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1823347","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:46:31Z","timestamp":1781671591000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Ke-qian","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Xiangtan Central Hospital, The Affiliated Hospital of Hunan University","place":["Xiangtan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, The First People's Hospital of Loudi","place":["Loudi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Fu","family":"Peng","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Shaoyang Polytechnic","place":["Shaoyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xiangtan Central Hospital, The Affiliated Hospital of Hunan University","place":["Xiangtan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Xiangtan Central Hospital, The Affiliated Hospital of Hunan University","place":["Xiangtan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"101235","DOI":"10.1016\/j.gore.2023.101235","article-title":"Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: a case report","volume":"49","author":"Fellouah","year":"2023","journal-title":"Gynecol Oncol Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.21037\/tlcr-2025-341","article-title":"Successful rechallenge of immune checkpoint inhibitors after severe immune-related hepatitis, thyroiditis and hypophysitis in TMB-high NSCLC: a case report","volume":"14","author":"Zhou","year":"2025","journal-title":"Transl Lung Cancer Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e64703","DOI":"10.7759\/cureus.64703","article-title":"A case report of pembrolizumab-induced allergic hepatitis","volume":"16","author":"Nakatani","year":"2024","journal-title":"Cureus."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjcr\/ytaa214","article-title":"A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab)","volume":"4","author":"Salido Iniesta","year":"2020","journal-title":"Eur Heart J Case Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/1759-7714.14314","article-title":"A single dose of pembrolizumab treatment causing a profound and durable response in lung cancer","volume":"13","author":"Kondo","year":"2022","journal-title":"Thorac Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e9431","DOI":"10.1097\/MD.0000000000009431","article-title":"Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: a case report","volume":"96","author":"Wu","year":"2017","journal-title":"Medicine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2021.07.021","article-title":"Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: case report and systematic review","volume":"160","author":"Tota","year":"2021","journal-title":"Lung Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1007\/s00261-025-04994-w","article-title":"Case of simultaneous occurrence of hepatitis, cholangitis, and pancreatitis as immune-related adverse events induced by immune checkpoint inhibitor therapy: a case report","volume":"50","author":"Kawata","year":"2025","journal-title":"Abdom Radiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"583781","DOI":"10.3389\/fonc.2020.583781","article-title":"Case Report: lymphocytosis associated with fatal hepatitis in a thymoma patient treated with anti-PD1: new insight into the immune-related storm","volume":"10","author":"Argentiero","year":"2020","journal-title":"Front Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"719236","DOI":"10.3389\/fmed.2021.719236","article-title":"Case report: severe immune-related cholestatic hepatitis and subsequent pneumonia after pembrolizumab therapy in a geriatic patient with metastic gastric cancer","volume":"8","author":"Yang","year":"2021","journal-title":"Front Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/iju5.12422","article-title":"Case study: a Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib","volume":"5","author":"Nishimoto","year":"2022","journal-title":"IJU Case Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.55729\/2000-9666.1486","article-title":"Case with refractory myasthenia gravis caused by pembrolizumab","volume":"15","author":"Amer","year":"2025","journal-title":"J Community Hosp Intern Med Perspect."},{"key":"B15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1159\/000507320","article-title":"Checkpoint inhibition causing complete remission of metastatic combined hepatocellular-cholangiocarcinoma after hepatic resection","volume":"13","author":"Rizell","year":"2020","journal-title":"Case Rep Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1164236","DOI":"10.3389\/fonc.2023.1164236","article-title":"Checkpoint inhibitor-induced gastritis followed by delayed severe hepatitis in a patient with lung metastases of head and neck squamous cell carcinoma: a case report","volume":"13","author":"Otsuka","year":"2023","journal-title":"Front Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"102192","DOI":"10.1016\/j.clinre.2023.102192","article-title":"Combination immune checkpoint therapy carried on despite grade 4 immune-related hepatotoxicity during treatment of metastatic melanoma: case report and review of literature","volume":"47","author":"Lallement","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1111\/1759-7714.13463","article-title":"Compromise or not? a case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol","volume":"11","author":"Liu","year":"2020","journal-title":"Thorac Cancer."},{"key":"B19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4103\/jpgm.jpgm_834_22","article-title":"Delayed immune-mediated hepatitis after three cycles of pembrolizumab for the treatment of sinonasal melanoma","volume":"69","author":"Kang","year":"2023","journal-title":"J Postgrad Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/CAD.0000000000001555","article-title":"Delayed immune-related hepatitis after 24 months of pembrolizumab treatment: a case report and literature review","volume":"35","author":"Salazar Gonz\u00e1lez","year":"2024","journal-title":"Anticancer Drugs."},{"key":"B21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2217\/imt-2021-0131","article-title":"Delayed immune-related neutropenia with hepatitis by pembrolizumab","volume":"14","author":"Nakako","year":"2022","journal-title":"Immunotherapy."},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.hemonc.2020.04.006","article-title":"Fatal autoimmune storm after a single cycle of anti-pd-1 therapy: a case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma","volume":"15","author":"Fuentes-Antr\u00e1s","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.pathol.2017.07.010","article-title":"Histopathology of pembrolizumab-induced hepatitis: a case report","volume":"49","author":"Aivazian","year":"2017","journal-title":"Pathology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1159\/000510740","article-title":"Immune checkpoint inhibitor-induced polymyositis and myasthenia gravis with fatal outcome","volume":"13","author":"Giglio","year":"2020","journal-title":"Case Rep Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e77331","DOI":"10.7759\/cureus.77331","article-title":"Immune Checkpoint Inhibitor-Induced Hepatitis: A Case Report of Challenging Management","volume":"17","author":"Soldin","year":"2025","journal-title":"Cureus."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2121109","DOI":"10.1080\/21645515.2022.2121109","article-title":"Long-term survival after immunotherapy and targeted therapy without chemotherapy in an elderly patient with HER2-positive gastroesophageal junction cancer: a case report","volume":"18","author":"Li","year":"2022","journal-title":"Hum Vaccin Immunother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e37606","DOI":"10.1097\/MD.0000000000037606","article-title":"Multiorgan failure caused by pembrolizumab and axitinib in a woman affected by metastatic clear cell renal cell carcinoma: a case report and literature review","volume":"103","author":"Di","year":"2024","journal-title":"Medicine."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1624","DOI":"10.1002\/cnr2.1624","article-title":"Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: a report of two cases and literature review","volume":"5","author":"Ueno","year":"2022","journal-title":"Cancer Rep."},{"key":"B29","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/jgh3.12554","article-title":"Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer","volume":"5","author":"Asatani","year":"2021","journal-title":"JGH Open."},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.55729\/2000-9666.1172","article-title":"Overlapping hepatotoxicity and colitis associated with immune checkpoint inhibitors","volume":"13","author":"Malik","year":"2023","journal-title":"J Community Hosp Intern Med Perspect."},{"key":"B31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1159\/000509953","article-title":"Pembrolizumab-Induced Delayed-Onset Hepatitis","volume":"14","author":"Kanaoka","year":"2020","journal-title":"Case Rep Gastroenterol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e11522","DOI":"10.7759\/cureus.11522","article-title":"Pembrolizumab-induced immune-mediated hepatitis and concurrent hepatitis b reactivation in a patient with non-small cell lung cancer","volume":"12","author":"Kundumadam","year":"2020","journal-title":"Cureus."},{"key":"B33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13256-021-02722-8","article-title":"Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report","volume":"15","author":"Tian","year":"2021","journal-title":"J Med Case Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.7812\/TPP\/17-004","article-title":"Pembrolizumab-induced pancytopenia: a case report","volume":"21","author":"Atwal","year":"2017","journal-title":"Perm J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.22551\/2025.46.1201.10306","article-title":"Pembrolizumab-induced simultaneous and multiple immune-related adverse events including myasthenia gravis, myositis, hepatitis, and pityriasis lichenoides in a non-small cell lung cancer patient","volume":"12","author":"Han","year":"2025","journal-title":"Arch Clin Cases."},{"key":"B36","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1159\/000518128","article-title":"Pembrolizumab treatment-induced liver toxicity","volume":"15","author":"Calderon","year":"2021","journal-title":"Case Rep Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"5908411","DOI":"10.1155\/2022\/5908411","article-title":"Plasmapheresis for pembrolizumab-induced hepatitis in a patient with squamous cell carcinoma and prior orthotopic liver transplantation","volume":"2022","author":"Al-Nattah","year":"2022","journal-title":"Case Rep Hepatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1159\/000542598","article-title":"Steroid-refractory immune-related hepatitis caused by pembrolizumab with stage ivb non-small cell lung cancer: a case report","volume":"19","author":"Hamaguchi","year":"2025","journal-title":"Case Rep Gastroenterol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.cllc.2019.02.004","article-title":"Successful retreatment using pembrolizumab for non-small-cell lung cancer after severe immune-related hepatitis: a case report","volume":"21","author":"Kobayashi","year":"2020","journal-title":"Clin Lung Cancer."},{"key":"B40","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2147\/OTT.S361467","article-title":"Successful treatment with short-term steroid against severe hepatitis confirmed by liver biopsy in a patient with advanced squamous-cell lung cancer receiving a combination of pembrolizumab, carboplatin, and nab-paclitaxel: a case report","volume":"15","author":"Hayashi","year":"2022","journal-title":"OncoTargets Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s40425-019-0727-5","article-title":"Unchecked immunity: a unique case of sequential immune-related adverse events with pembrolizumab","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B42","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/curroncol28010088","article-title":"Very delayed acute hepatitis after pembrolizumab therapy for advanced malignancy: how long should we watch?","volume":"28","author":"Phan","year":"2021","journal-title":"Curr Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00262-017-2107-7","article-title":"Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report","volume":"67","author":"McGuire","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1616361","DOI":"10.3389\/fimmu.2025.1616361","article-title":"Lysine methyltransferase 2D deficiency drives complete response to pembrolizumab in PD-L1-High cholangiocarcinoma: a case report and review of literature","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2217\/imt-2021-0342","article-title":"Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report","volume":"14","author":"Lasagna","year":"2022","journal-title":"Immunotherapy."},{"key":"B46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/hep.1840100125","article-title":"Acute massive necrosis of the liver induced by antibody\/complement, not by T-cells","volume":"10","author":"Okuda","year":"1989","journal-title":"Hepatology."},{"key":"B47","doi-asserted-by":"publisher","first-page":"990","DOI":"10.4049\/jimmunol.134.2.990","article-title":"Effect of B cell differentiation factor (BCDF) on biosynthesis and secretion of immunoglobulin molecules in human B cell lines","volume":"134","author":"Kikutani","year":"1985","journal-title":"J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41423-021-00768-8","article-title":"Autoimmmune hepatitis","volume":"19","author":"Terziroli Beretta-Piccoli","year":"2022","journal-title":"Cell Mol Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.3748\/wjg.v28.i24.2654","article-title":"Drug-induced autoimmune hepatitis: a minireview","volume":"28","author":"Tan","year":"2022","journal-title":"World J Gastroenterol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","article-title":"Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids","volume":"66","author":"Ziemer","year":"2017","journal-title":"J Hepatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1002\/hep.21060","article-title":"The liver as an immunological organ","volume":"43","author":"Racanelli","year":"2006","journal-title":"Hepatology."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.4049\/jimmunol.173.7.4433","article-title":"Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells","volume":"173","author":"Moseman","year":"2004","journal-title":"J Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"6922","DOI":"10.4049\/jimmunol.0900582","article-title":"NOD2 ligation subverts IFN-alpha production by liver plasmacytoid dendritic cells and inhibits their T cell allostimulatory activity via B7-H1 up-regulation","volume":"183","author":"Castellaneta","year":"2009","journal-title":"J Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2015.08.020","article-title":"Immunity, tolerance and autoimmunity in the liver: a comprehensive review","volume":"66","author":"Doherty","year":"2016","journal-title":"J Autoimmun."},{"key":"B55","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.21965","article-title":"Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance","volume":"47","author":"Diehl","year":"2008","journal-title":"Hepatology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/imm.13141","article-title":"Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms","volume":"159","author":"Fessas","year":"2020","journal-title":"Immunology."},{"key":"B57","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41424-018-0049-9","article-title":"Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis","volume":"9","author":"Reddy","year":"2018","journal-title":"Clin Transl Gastroenterol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"B59","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo-Sifiliogr"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1823347\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:46:36Z","timestamp":1781671596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1823347\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":59,"alternative-id":["10.3389\/fmed.2026.1823347"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1823347","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1823347"}}